Esophageal diseases

Wolf, W. Asher; Dellon, Evan S.; Shaheen, Nicholas J.

doi:10.1016/j.gie.2014.07.001

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 However, recent studies have noted recurrence of IM and dysplasia in up to 33% of patients at 2 years underscoring the need for postablation surveillance. 26 Another recent analysis from the US RFA registry showed that the incidence rate of 27,28 A multicenter study from Europe looked at predictors of poor response to initial RFA treatment in patients treated for HGD. Four independent baseline predictors of poor response were observed: active reflux esophagitis (odds ratio [OR] 38; 95% CI, 3.2-4.33), endoscopic resection scar regeneration with Barrett's epithelium (OR, 4.7; 95 %CI, 1.1-20.0), esophageal narrowing pre-RFA (OR, 3.9; 95% CI, 1.0-15.1), and years of neoplasia pre-RFA (OR, 1.2; 95% CI, 1.0-1.4).…”

Section: Discussionmentioning

confidence: 99%

Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia

Peter

Mönkemüller

2015

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia

Peter

Mönkemüller

2015

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Ingestible devices for long-term gastrointestinal residency: a review

2021

View full text Add to dashboard Cite

Ingestible devices have been gaining attention from the medical community due to their noninvasive use in diagnostics and treatment of the gastrointestinal (GI) tract. However, their passive locomotion limits their GI residency period. Ingestible sensors residing in the GI tract are capable of providing continuous data, while long-acting ingestible drug delivery systems can reduce medication nonadherence. This paper presents a comprehensive overview of the state-of-the-art, long-term ingestible devices (LTIDs). Additionally, this review summarizes the current status of ingestible devices that persist in the GI tract for a prolonged period, as well as their inhabitance mechanisms and applications. Also included are relevant information about the GI structure and design considerations for understanding the significance and challenges associated with LTIDs. Finally, we discuss several potential applications of the LTIDs for therapeutic intervention in the GI tract and monitoring the physiology and pathophysiology of the GI tract for an extended period.

show abstract

Esophageal diseases

Cited by 2 publications

References 15 publications

Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia

Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia

Ingestible devices for long-term gastrointestinal residency: a review

Contact Info

Product

Resources

About